These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33513737)

  • 1. Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease.
    Kosyakovsky J; Fine JM; Frey WH; Hanson LR
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33513737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry.
    Kosyakovsky J; Witthuhn BA; Svitak AL; Frey WH; Hanson LR; Fine JM
    ACS Chem Neurosci; 2019 Nov; 10(11):4571-4578. PubMed ID: 31573798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.
    Guo C; Hao LJ; Yang ZH; Chai R; Zhang S; Gu Y; Gao HL; Zhong ML; Wang T; Li JY; Wang ZY
    Exp Neurol; 2016 Jun; 280():13-23. PubMed ID: 26996132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
    Fine JM; Forsberg AC; Stroebel BM; Faltesek KA; Verden DR; Hamel KA; Raney EB; Crow JM; Haase LR; Knutzen KE; Kaczmarczek KD; Frey WH; Hanson LR
    J Neurol Sci; 2017 Sep; 380():164-171. PubMed ID: 28870559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
    Fine JM; Renner DB; Forsberg AC; Cameron RA; Galick BT; Le C; Conway PM; Stroebel BM; Frey WH; Hanson LR
    Neurosci Lett; 2015 Jan; 584():362-7. PubMed ID: 25445365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
    Guo X; Qi X; Li H; Duan Z; Wei Y; Zhang F; Tian M; Ma L; You C
    World Neurosurg; 2019 Aug; 128():e895-e904. PubMed ID: 31082547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement.
    Fine JM; Kosyakovsky J; Baillargeon AM; Tokarev JV; Cooner JM; Svitak AL; Faltesek KA; Frey WH; Hanson LR
    Brain Behav; 2020 Mar; 10(3):e01536. PubMed ID: 31960628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile.
    Nasrallah GK; Salem R; Da'as S; Al-Jamal OLA; Scott M; Mustafa I
    Neurotoxicol Teratol; 2019; 72():29-38. PubMed ID: 30710618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain.
    Guo C; Wang P; Zhong ML; Wang T; Huang XS; Li JY; Wang ZY
    Neurochem Int; 2013 Jan; 62(2):165-72. PubMed ID: 23262393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.
    Hanson LR; Fine JM; Renner DB; Svitak AL; Burns RB; Nguyen TM; Tuttle NJ; Marti DL; Panter SS; Frey WH
    Drug Deliv Transl Res; 2012 Jun; 2(3):160-8. PubMed ID: 25786865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial.
    Millán M; DeGregorio-Rocasolano N; Pérez de la Ossa N; Reverté S; Costa J; Giner P; Silva Y; Sobrino T; Rodríguez-Yáñez M; Nombela F; Campos F; Serena J; Vivancos J; Martí-Sistac O; Cortés J; Dávalos A; Gasull T
    Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
    Fine JM; Forsberg AC; Renner DB; Faltesek KA; Mohan KG; Wong JC; Arneson LC; Crow JM; Frey WH; Hanson LR
    Brain Res; 2014 Jul; 1574():96-104. PubMed ID: 24928620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
    Liu Z; Lin TM; Purro M; Xiong MP
    ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.